New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...
Given the near-constant technological advancements in AI, potential AI policy updates, and regulatory changes, flexible AI ...
LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous ...
Adaptability serves as the foundation for lasting career success, shaping leaders who can thrive in an ever-changing business ...
Falsified medicines are fakes that get into the supply chain, often via the Internet. These could be tablets or injectables that have the wrong amount of the right drug, with a dose that is too low or ...
Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...
A: TODAY, WE ARE USED TO SEEING SHAREHOLDERS use proxy battles to insert their representatives into the board of directors (eg. Medicines Company and Ariad). Further, the makeup of a typical company’s ...
Then: In the May 2023 issue of Life Science Leader, Bobak Azamian, MD, Ph.D., cofounder and CEO of Tarsus Pharmaceuticals, talked about the company’s formation in 2016, and the decision to focus on ...
Oxygen, crucial for cellular respiration, is affected by pressure variations within a bioreactor, with higher pressure at the bottom leading to increased oxygen solubility. This heterogeneity is ...
In the life sciences sector, maintaining a strategic approach to tax planning has become increasingly complex, especially with ongoing regulatory changes affecting mergers, acquisitions, and how we ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果